JUL 29, 2019 07:57 AM PDT

Medications Used for Atrial fibrillation May Increase Falls

WRITTEN BY: Nouran Amin

Falls among older adults are a growing health concern that often lead to injury, hospitalization, and other severe complications. Older adults are even at a higher risk of falling with debilitating chronic conditions and being prescribed certain drugs.

For example, atrial fibrillation—a condition characterized by the rapid contraction in one region of the heart—is most common among adults over 65 and is one of the major contributors to falling and fainting.

Learn more about atrial fibrillation:

Treatments for atrial fibrillation often include beta-blockers, certain calcium channel blockers (diltiazem, verapamil), and digoxin. Others drugs may also include amiodarone, flecainide, and propafenone. Unfortunately, these treatments increase the risk of falling among older adults but the connection to how this happens has not been studied until now

In a publication in the Journal of the American Geriatrics Society, researchers used data generated from Danish health records of atrial fibrillation patients between 65 and 100 years who were prescribed treatments. The researchers then examined those patients who had hospital admissions for falls or fainting and who suffered fall-related injuries such as varying degrees of head injuries or a fractured thigh, elbow, forearm, wrist, shoulder or upper arm, pelvis, and skull.

Results showed that patients who took amiodarone were at a significant risk of falling whether on short-term or long-term treatment and the medication digoxin held a slight association with fall-related injuries. In addition, treatments taken within the first 90 days, particularly the first two weeks, contributed to an even higher risk of injury.

"Our findings add evidence that, for older patients with atrial fibrillation, treatment with amiodarone is associated with a higher risk of fall-related injuries and fainting," stated the researchers.

Overall, the findings conclude the critical importance of health care providers weighing the pros and cons of reporting atrial fibrillation treatments to patients and the potential risk it may cause regarding their safety and patient care.

Source: Health in Aging

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 15, 2019
Genetics & Genomics
NOV 15, 2019
How Epigenetics Could Cure Addiction
Addictive behavior is characterized by relapse- being triggered by environmental factors to re-engage in harmful behavior from drug abuse to self harm. One...
NOV 15, 2019
Drug Discovery & Development
NOV 15, 2019
Injectable Implant Drug Shows Promise for HIV Treatment
In a study published in Nature Communications, alternative treatment was shown to have promising results for HIV as opposed to a daily pill regimen. Scient...
NOV 15, 2019
Drug Discovery & Development
NOV 15, 2019
Peptide-Based Therapeutics Advances Alzheimer Disease Research
Affecting 44 million individuals globally, Alzheimer’s disease (AD) is a form of dementia characterized by loss of brain cells, inflammation and vasc...
NOV 15, 2019
Drug Discovery & Development
NOV 15, 2019
Evolutionary-Busting Cancer Drug
Researchers at the Institute of Cancer Research in London have discovered that a new type of drug that blocks treatment in cancers. The drug works by inhib...
NOV 15, 2019
Health & Medicine
NOV 15, 2019
FDA Cautions Against Cannabis Use During Pregnancy
A recent article published by NPR addresses the rapidly growing number of females using cannabis during pregnancy. Those with tough pregnancy side effects ...
NOV 15, 2019
Drug Discovery & Development
NOV 15, 2019
Promising Results for New Vaccine Against Dengue Fever
Dengue fever is an illness transmitted by mosquito bites. Affecting around 390 million people per year, if left untreated, its mortality rate is 20%. Altho...
Loading Comments...